DOI: https://doi.org/10.30978/MG-2019-4-106

Рекомендації Європейської асоціації з вивчення печінки (EASL) щодо харчування хворих з хронічними захворюваннями печінки.* Частина 3

O. G. Kurinna

Анотація


-

Ключові слова


-

Повний текст:

PDF

Посилання


Guanabens N., Pares A. Liver and bone. Arch Biochem Biophys. 2010;503:84-94.

Compston J. E. Hepatic osteodystrophy: vitamin D metabolism inpatients with liver disease. Gut. 1986;27:1073-1090.

Assessment of fracture risk and its application to screening forpostmenopausal osteoporosis. Report of a WHO Study Group. WHO Tech Rep Ser. 1994;843:1-129.

Menon K. V., Angulo P., Weston S., Dickson E. R., Lindor K. D. Bone disease inprimary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001;35:316-323.

Pares A., Guanabens N., Alvarez L. et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms andbone mass in primary biliary cirrhosis. Hepatology. 2001;33:554-560.

Guanabens N., Pares A., Ros I. et al. Severityof cholestasis and advanced histological stage but not menopausalstatus are the major risk factors for osteoporosis in primary biliarycirrhosis. J Hepatol. 2005;42:573-577.

Guichelaar M. M., Kendall R., Malinchoc M., Hay J. E. Bone mineral densitybefore and after OLT: long-term follow-up and predictive factors. Liver Transpl. 2006;12:1390-1402.

Guanabens N., Cerda D., Monegal A. et al. Low bone mass and severity of cholestasis affect fracture risk inpatients with primary biliary cirrhosis. Gastroenterology. 2010;138:2348-2356.

Angulo P., Grandison G. A., Fong D. G. et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011;140:180-188.

Diamond T., Stiel D., Lunzer M., Wilkinson M., Roche J., Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut. 1990;31:82-87.

Chen C. C., Wang S. S., Jeng F. S., Lee S. D. Metabolic bone disease of livercirrhosis: is it parallel to the clinical severity of cirrhosis?. J Gastroenterol Hepatol. 1996;11:417-421.

Monegal A., Navasa M., Guanabens N. et al. Osteoporosis and bone mineral metabolism disorders incirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int. 1997;60:148-154.

Ninkovic M., Skingle S. J., Bearcroft P. W., Bishop N., Alexander G. J., Compston JE. Incidence of vertebral fractures in the first three months afterorthotopic liver transplantation. Eur J Gastroenterol Hepatol. 2000;12:931-935.

Carey E. J., Balan V., Kremers W. K., Hay JE. Osteopenia and osteoporosis inpatients with end-stage liver disease caused by hepatitis C andalcoholic liver disease: not just a cholestatic problem. Liver Transpl. 2003;9:1166-1173.

Gonzalez-Calvin J. L., Mundi J. L. Bone mineral density and serum levels of soluble tumornecrosis factors, estradiol, and osteoprotegerin in postmenopausalwomen with cirrhosis after viral hepatitis. J Clin Endocrinol Metab. 2009;94:4844-4850.

Monegal A., Navasa M., Peris P. et al. Bone disease in patients awaiting liver transplantation. Has thesituation improved in the last two decades?. Calcif Tissue Int. 2013;93:571-576.

Sinigaglia L., Fargion S., Fracanzani A. L. et al. Bone and joint involvement in genetic hemochromatosis: roleof cirrhosis and iron overload. J Rheumatol. 1997;24:1809-1813.

Guggenbuhl P., Deugnier Y., Boisdet J. F. et al. Bone mineral density in men with genetic hemochromatosisand HFE gene mutation. Osteoporos Int. 2005;16:1809-1814.

Valenti L., Varenna M., Fracanzani A. L., Rossi V., Fargion S., Sinigaglia L. Association between iron overload and osteoporosis in patients withhereditary hemochromatosis. Osteoporos Int. 2009;20:549-555.

Guanabens N., Pares A., Navasa M. et al. Cyclosporin A increases the biochemical markers of boneremodeling in primary biliary cirrhosis. J Hepatol. 1994;21:24-28.

Springer J. E., Cole D. E., Rubin L. A. et al. Vitamin D-receptor genotypes as independent genetic predictorsof decreased bone mineral density in primary biliary cirrhosis. Gastroenterology. 2000;118:145-151.

Newton J., Francis R., Prince M. et al. Osteoporosis in primary biliary cirrhosis revisited. Gut. 2001;49:282-287.

Solerio E., Isaia G., Innarella R. et al. Osteoporosis: still a typical complication of primary biliary cirrhosis?. Dig Liver Dis. 2003;35:339-346.

Bonkovsky H. L., Hawkins M., Steinberg K. et al. Prevalence and prediction of osteopenia in chronicliver disease. Hepatology. 1990;12:273-280.

Ninkovic M., Love S. A., Tom B., Alexander G. J., Compston J. E. Highprevalence of osteoporosis in patients with chronic liver disease priorto liver transplantation. Calcif Tissue Int. 2001;69:321-326.

Sokhi R. P., Anantharaju A., Kondaveeti R. et al. Bone mineral density among cirrhotic patients awaiting livertransplantation. Liver Transpl. 2004;10:648-653.

Olsson R., Johansson C., Lindstedt G., Mellstrom D. Risk factors for boneloss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol. 1994;29:753-756.

Monegal A., Navasa M., Guanabens N. et al. Bone disease after liver transplantation: a long-termprospective study of bone mass changes, hormonal status and histomorphometriccharacteristics. Osteoporos Int. 2001;12:484-492.

Leidig-Bruckner G., Hosch S., Dodidou P. et al. Frequency and predictors of osteoporotic fractures after cardiac orliver transplantation: a follow-up study. Lancet. 2001;357:342-347.

Navasa M., Monegal A., Guanabens N. et al. Bone fractures in liver transplant patients. Br J Rheumatol. 1994;33:52-55.

Compston J. E. Osteoporosis after liver transplantation. Liver Transpl. 2003;9:321-330.

Pares A., Guanabens N. Treatment of bone disorders in liver disease. J Hepatol. 2006;45:445-453.

Dasarathy J., Varghese R., Feldman A., Khiyami A., McCullough A. J., Dasarathy S. Patients with nonalcoholic fatty liver disease have a lowresponse rate to vitamin D supplementation. J Nutr. 2017.

Guanabens N., Pares A., Alvarez L. et al. Collagen-related markers of bone turnover reflect theseverity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res. 1998;13:731-738.

Guanabens N., Monegal A., Muxi A. et al. Patients with cirrhosis and ascites have false valuesof bone density: implications for the diagnosis of osteoporosis. Osteoporos Int. 2012;23:1481-1487.

Guanabens N., Pares A., Monegal A. et al. Etidronate versus fluoride for treatment of osteopenia in primarybiliary cirrhosis: preliminary results after 2 years. Gastroenterology. 1997;113:219-224.

Guanabens N., Pares A., Ros I. et al. Alendronate is more effective than etidronate for increasing bone massin osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2268-2274.

Lindor K. D., Jorgensen R. A., Tiegs R. D. et al. Etidronate forosteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol. 2000;33:878-882.

Wolfhagen F. H., van Buuren H. R., den Ouden J. W. et al. Cyclical etidronate in the prevention of bone lossin corticosteroid-treated primary biliary cirrhosis. A prospective,controlled pilot study. J Hepatol. 1997;26:325-330.

Guanabens N., Monegal A., Cerda D. et al. Randomized trial comparing monthly ibandronate and weekly alendronatefor osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58:2070-2078.

Zein C. O., Jorgensen R. A., Clarke B. et al. Alendronate improves bone mineral density in primary biliary cirrhosis:a randomized placebo-controlled trial. Hepatology. 2005;42:762-771.

Ninkovic M., Love S., Tom B. D. et al. Lack of effect of intravenous pamidronate on fracture incidence andbone mineral density after orthotopic liver transplantation. J Hepatol. 2002;37:93-100.

Monegal A., Guanabens N., Suarez M. J. et al. Pamidronate in the prevention of bone loss after livertransplantation: a randomized controlled trial. Transpl Int. 2009;22:198-206.

Millonig G., Graziadei I. W., Eichler D. et al. Alendronate in combination with calcium andvitamin D prevents bone loss after orthotopic liver transplantation: aprospective single-center study. Liver Transpl. 2005;11:960-966.

Crawford B. A., Kam C., Pavlovic J. et al. Zoledronic acid prevents bone loss after liver transplantation: arandomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144:239-248.

Atamaz F., Hepguler S., Akyildiz M., Karasu Z., Kilic M. Effects ofalendronate on bone mineral density and bone metabolic markers inpatients with liver transplantation. Osteoporos Int. 2006;17:942-949.

Olsson R., Mattsson L. A., Obrant K., Mellstrom D. Estrogen-progestogentherapy for low bone mineral density in primary biliary cirrhosis. Liver. 1999;19:188-192.

Pereira S. P., O’Donohue J., Moniz C. et al. Transdermal hormone replacement therapy improvesvertebral bone density in primary biliary cirrhosis: results of a 1-yearcontrolled trial. Aliment Pharmacol Ther. 2004;19:563-570.

Ormarsdottir S., Mallmin H., Naessen T. et al. An open, randomized, controlled study of transdermalhormone replacement therapy on the rate of bone loss in primarybiliary cirrhosis. J Intern Med. 2004;256:63-69.

Isoniemi H., Appelberg J., Nilsson C. G. et al. Transdermal oestrogen therapy protects postmenopausal liver transplantwomen from osteoporosis. A 2-year follow-up study. J Hepatol. 2001;34:299-305.

Diamond T., Stiel D., Posen S. Effects of testosterone and venesection onspinal and peripheral bone mineral in six hypogonadal men withhemochromatosis. J Bone Miner Res. 1991;6:39-43.

Nagasue N., Yukaya H., Chang Y. C. et al. Active uptakeof testosterone by androgen receptors of hepatocellular carcinoma inhumans. Cancer. 1986;57:2162-2167.

Dresner-Pollak R., Gabet Y., Steimatzky A. et al. Human parathyroid hormone 1-34 prevents bone loss inexperimental biliary cirrhosis in rats. Gastroenterology. 2008;134:259-267.

Keeffe E. B., Gettys C., Esquivel C. O. Liver transplantation in patients withsevere obesity. Transplantation. 1994;57:309-311.

Sawyer R. G., Pelletier S. J., Pruett T. L. Increased early morbidity andmortality with acceptable long-term function in severely obese patientsundergoing liver transplantation. Clin Transplant. 1999;13:126-130.

Nair S., Verma S., Thuluvath P. J. Obesity and its effect on survival inpatients undergoing orthotopic liver transplantation in the UnitedStates. Hepatology. 2002;35:105-109.

Dick A. A., Spitzer A. L., Seifert C. F. et al. Liver transplantation at the extremes of the body mass index. Transpl. 2009;15:968-977.

Leonard J., Heimbach J., Malinchoc M., Watt K., Charlton M. The impact ofobesity on long-term outcomes in liver transplant recipients—results ofthe NIDDK liver transplant database. Am J Transplant. 2008;8:667-672.

Merli M., Giusto M., Gentili F. et al. Nutritional status: its influence on the outcome of patients undergoingliver transplantation. Liver Int. 2010;30:208-214.

Pikul J., Sharpe M. D., Lowndes R., Ghent C. N. Degree of preoperativemalnutrition is predictive of postoperative morbidity and mortality inliver transplant recipients. Transplantation. 1994;57:469-472.

Harrison J., McKiernan J., Neuberger J. M. A prospective study on theeffect of recipient nutritional status on outcome in liver transplantation. Transpl Int. 1997;10:369-374.

Selberg O., Bottcher J., Tusch G. et al. Identification of high-and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parametersin 150 patients. Hepatology. 1997;25:652-657.

Englesbe M. J., Patel S. P., He K. et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010;211:271-278.

Tandon P., Ney M., Irwin I., Ma M. M. et al. Severemuscle depletion in patients on the liver transplant wait list: itsprevalence and independent prognostic value. Liver Transpl. 2012;18:1209-1216.

Montano-Loza A. J., Meza-Junco J., Prado C. M. et al. Muscle wasting is associated with mortality in patientswith cirrhosis. Clin Gastroenterol Hepatol. 2012;10:166-173.

DiMartini A., Cruz R. J., Dew M. A. et al. Muscle mass predicts outcomes following liver transplantation. Transpl. 2013;19:1172-1180.

Durand F., Buyse S., Francoz C. et al. Prognostic value of muscle atrophy in cirrhosis using psoas musclethickness on computed tomography. J Hepatol. 2014;60:1151-1157.

Yadav A., Chang Y. H., Carpenter S. et al. Relationship between sarcopenia, six-minute walk distance and healthrelatedquality of life in liver transplant candidates. Clin Transplant. 2015;29:134-141.

Wang C. W., Feng S., Covinsky K. E. et al. Acomparison of muscle function, mass, and quality in liver transplantcandidates: results from the functional assessment in liver transplantationstudy. Transplantation. 2016;100:1692-1698.

Dunn M. A., Josbeno D. A., Schmotzer A. R. et al. The gap between clinically assessed physicalperformance and objective physical activity in liver transplant candidates. Liver Transpl. 2016;22:1324-1332.

Lai J. C., Volk M. L., Strasburg D., Alexander N. Performance-based measuresassociate with frailty in patients with end-stage liver disease. Transplantation. 2016;100:2656-2660.

Kalafateli M., Mantzoukis K., Choi Yau Y. et al. Malnutrition and sarcopenia predict post-livertransplantation outcomes independently of the Model for End-stageLiver Disease score. J Cachexia Sarcopenia Muscle. 2017;8:113-121.

Sinclair M., Poltavskiy E., Dodge J. L., Lai J. C. Frailty is independentlyassociated with increased hospitalisation days in patients on the livertransplant waitlist. World J Gastroenterol. 2017;23:899-905.

Ferreira L. G., Ferreira Martins A. I., Cunha C. E. et al. Negative energy balance secondary to inadequate dietaryintake of patients on the waiting list for liver transplantation. Nutrition. 2013;29:1252-1258.

Ney M., Abraldes J. G., Ma M. et al. Insufficient protein intake is associated with increased mortality in 630patients with cirrhosis awaiting liver transplantation. Nutr Clin Pract. 2015;30:530-536.

Le Cornu K. A., McKiernan F. J., Kapadia S. A., Neuberger J. M. A prospectiverandomized study of preoperative nutritional supplementation inpatients awaiting elective orthotopic liver transplantation. Transplantation. 2000;69:1364-1369.

Plank L. D., McCall J. L., Gane E. J. et al. Pre- and postoperative immunonutrition in patients undergoing livertransplantation: a pilot study of safety and efficacy. Clin Nutr. 2005;24:288-296.

Plank L. D., Mathur S., Gane E. J., Peng S. L., Gillanders L. K., McIlroy K et al. Perioperative immunonutrition in patients undergoing liver transplantation:a randomized double-blind trial. Hepatology. 2015;61:639-647.

Lei Q., Wang X., Zheng H., Bi J., Tan S., Li N. Peri-operative immunonutritionin patients undergoing liver transplantation: a meta-analysis ofrandomized controlled trials. Asia Pac J Clin Nutr. 2015;24:583-590.

Kaido T., Mori A., Ogura Y. et al. Impact ofenteral nutrition using a new immuno-modulating diet after livertransplantation. Hepatogastroenterology. 2010;57:1522-1525.

Hanai T., Shiraki M., Nishimura K. et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31:193-199.

Garrison R. N., Cryer H. M., Howard D. A., Polk JrH. Clarification of riskfactors for abdominal operations in patients with hepatic cirrhosis. Ann Surg. 1984;199:648.

Merli M., Nicolini G., Angeloni S., Riggio O. Malnutrition is a risk factor incirrhotic patients undergoing surgery. Nutrition. 2002;18:978-986.

Swart G., Van den Berg J., Van Vuure J. et al. Minimum protein requirements in liver cirrhosis determined bynitrogen balance measurements at three levels of protein intake. Clin Nutrition. 1989;8:329-336.

Zillikens M., Van den Berg J., Wattimena J. et al. Nocturnaloral glucose supplementation: the effects on protein metabolism incirrhotic patients and in healthy controls. J Hepatol. 1993;17:377-383.

Coolsen M. M., Wong-Lun-Hing E. M., Dam R. M. et al. A systematic review of outcomes in patients undergoing liversurgery in an enhanced recovery after surgery pathways. HPB. 2013;15:245-251.

Hughes M. J., McNally S., Wigmore S. J. Enhanced recovery following liversurgery: a systematic review and meta-analysis. HPB. 2014;16:699-706.

Weimann A., Braga M., Carli F. et al. ESPenteral nutrition guideline: Clinical nutrition in surgery. Clinicalnutrition. 2017;36:623-650.

Reilly J., Mehta R., Teperman L. et al. Nutritional support after liver transplantation: a randomized prospectivestudy. J Parenter Enteral Nutr. 1990;14:386-391.

Hasse J. M., Blue L. S., Liepa G. U. et al. Early enteral nutrition support in patients undergoing liver transplantation. J Parenter Enteral Nutr. 1995;19:437-443.

Wicks C., Routley D., Williams R. et al. Comparison of enteral feeding and total parenteral nutrition afterliver transplantation. Lancet. 1994;344:837-840.

Rayes N., Seehofer D., Hansen S. et al. Early enteral supply of lactobacillus and fiber versus selective boweldecontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74:123-127.

Pescovitz M. D., Mehta P. L., Leapman S. B. et al. Tube jejunostomy in liver transplant recipients. Surgery. 1995;117:642-647.

Mehta P. L., Alaka K. J., Filo R. S. et al. Nutrition support following liver transplantation: comparison ofjejunal versus parenteral routes. Clin Transplant. 1995;9:364-369.

Hu Q.-G., Zheng Q.-C. The influence of enteral nutrition in postoperativepatients with poor liver function. World J Gastroenterol. 2003;9:843.

Plank L. D., Metzger D. J., McCall J. L. et al. Sequential changes in the metabolic response to orthotopic livertransplantation during the first year after surgery. Ann Surg. 2001;234:245.

Weijs P. J., Cynober L., DeLegge M. et al. Proteins and amino acids are fundamental to optimal nutrition supportin critically ill patients. Crit Care. 2014;18:591.

McClave S. A., DiBaise J. K., Mullin G. E., Martindale R. G. ACG Clinical Guideline: nutrition therapy in the adult hospitalized patient. Am J Gastroenterol. 2016;111:315-334, quiz 335.

McClave S. A., Taylor B. E., Martindale R. G. et al. Guidelines for the provision and assessment ofnutrition support therapy in the adult critically ill patient: Society ofCritical Care Medicine (SCCM) and American Society for Parenteral andEnteral Nutrition (A.S.P. E.N.). JPEN J Parenter Enteral Nutr. 2016;40:159-211.

Kyoung K.-H., Lee S.-G., Nam C. W., Nah Y. W. Beneficial effect of low caloricintake in the early period after orthotopic liver transplantation: a newconcept using graft weight. Hepatogastroenterology. 2014;61:1668-1672.

Marik P. E. Is early starvation beneficial for the critically ill patient?. Curr Opin Clin Nutr Metab Care. 2016;19:155-160.

Zhu X., Wu Y., Qiu Y., Jiang C., Ding Y. Effects of omega-3 fish oil lipidemulsion combined with parenteral nutrition on patients undergoingliver transplantation. JPEN J Parenter Enteral Nutr. 2013;37:68-74.

Zhu X. H., Wu Y. F., Qiu Y. D. et al. Liver-protecting effects ofomega-3 fish oil lipid emulsion in liver transplantation. World J Gastroenterol. 2012;18:6141-6147.

Kuse E. R., Kotzerke J., Müller S., Nashan B., Lück R., Jaeger K. Hepaticreticuloendothelial function during parenteral nutrition including anMCT/LCT or LCT emulsion after liver transplantation–a double-blindstudy. Transpl Int. 2002;15:272-277.

McClave S. A., Kushner R., Van Way CW. 3rd et al. Nutrition therapy of the severely obese, critically ill patient:summation of conclusions and recommendations. JPEN J Parenterenteral Nutr. 2011;35:88S–96S.

Lundbom N., Laurila O., Laurila S. Central pontine myelinolysis aftercorrection of chronic hyponatraemia. Lancet. 1993;342:247-248.

Mcdiarmid S. V., John O Colonna I., Shaked A., Ament M. E., Busuttil R. W. Acomparison of renal function in cyclosporine-and FK-506-treatedpatients after primary orthotopic liver transplantation. Transplantation. 1993;56:847-853.

Murray M., Grogan T. A., Lever J., Warty V. S., Fung J., Venkataramanan R. Comparison of tacrolimus absorption in transplant patients receivingcontinuous versus interrupted enteral nutritional feeding. Ann Pharmacother. 1998;32:633-636.

Richards J., Gunson B., Johnson J., Neuberger J. Weight gain and obesityafter liver transplantation. Transpl Int. 2005;18:461-466.

Laryea M., Watt K. D., Molinari M. et al. Metabolic syndrome in liver transplant recipients: prevalence andassociation with major vascular events. Liver Transpl. 2007;13:1109-1114.

Bianchi G., Marchesini G., Marzocchi R., Pinna A. D., Zoli M. Metabolicsyndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl. 2008;14:1648-1654.

Schutz T., Hudjetz H., Roske A. E. et al. Weight gain in long-term survivors of kidney or liver transplantation–another paradigm of sarcopenic obesity?. Nutrition. 2012;28:378-383.

Krasnoff J. B., Vintro A. Q., Ascher N. L., Bass N. M., Dodd M. J., Painter P. L. Objective measures of health-related quality of life over 24 monthspost-liver transplantation. Clin Transplant. 2005;19:1-9.

Krasnoff J. B., Vintro A. Q., Ascher N. L. et al. Arandomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant. 2006;6:1896-1905.

Roman E., Torrades M. T., Nadal M. J. et al. Randomized pilot study: effects of an exercise programme and leucinesupplementation in patients with cirrhosis. Dig Dis Sci. 2014;59:1966-1975.

Harimoto N., Shirabe K., Yamashita Y. I. et al. Sarcopenia as a predictor of prognosis in patients followinghepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100:1523-1530.

Voron T., Tselikas L., Pietrasz D. et al. Sarcopenia impacts on short- and long-term results of hepatectomy forhepatocellular carcinoma. Ann Surg. 2015;261:1173-1183.

Kanematsu T., Koyanagi N., Matsumata T., Kitano S., Takenaka K., Sugimachi K. Lack of preventive effect of branched-chain amino acidsolution on postoperative hepatic encephalopathy in patients withcirrhosis: a randomized, prospective trial. Surgery. 1988;104:482-488.

Tang Z. F., Ling Y. B., Lin N., Hao Z., Xu R. Y. Glutamine and recombinanthuman growth hormone protect intestinal barrier function followingportal hypertension surgery. World J Gastroenterol. 2007;13:2223-2228.

Plauth M, Cabre E, Riggio O et al. ESP enteral nutrition guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25:285-294.

Plauth M., Cabre E., Campillo B. et al. ESPenteral nutrition Guidelines on Parenteral Nutrition: hepatology. Clin Nutr. 2009;28:436-444.

Nielsen K., Kondrup J., Martinsen L. et al. Long-term oral refeeding of patients with cirrhosis of the liver. Br J Nutr. 1995;74:557-567.

Nielsen K., Kondrup J., Martinsen L., Stilling B., Wikman B. Nutritionalassessment and adequacy of dietary intake in hospitalized patientswith alcoholic liver cirrhosis. Br J Nutr. 1993;69:665-679.

Addolorato G., Capristo E., Greco A. V., Caputo F., Stefanini G. F., Gasbarrini G. Three months of abstinence from alcohol normalizes energy expenditureand substrate oxidation in alcoholics: a longitudinal study. Am J Gastroenterol. 1998;93:2476-2481.

Levine J. A., Harris M. M., Morgan M. Y. Energy expenditure in chronicalcohol abuse. Eur J Clin Invest. 2000;30:779-786.

Nasrallah S. M., Galambos J. T. Aminoacid therapy of alcoholic hepatitis. Lancet. 1980;2:1276-1277.

Morgan T. R., Moritz T. E., Mendenhall C. L., Haas R. Protein consumptionand hepatic encephalopathy in alcoholic hepatitis. VA CooperativeStudy Group #275. J Am Coll Nutr. 1995;14:152-158.

Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev. 2012;CD008344.

Antar R., Wong P., Ghali P. A meta-analysis of nutritional supplementationfor management of hospitalized alcoholic hepatitis. Can J Gastroenterol. 2012;26:463-467.

Cabre E., Rodriguez-Iglesias P., Caballeria J. et al. Short- and long-term outcome of severe alcoholinducedhepatitis treated with steroids or enteral nutrition: a multicenterrandomized trial. Hepatology. 2000;32:36-42.

Moreno C., Deltenre P., Senterre C. et al. Intensive enteral nutrition is ineffective for patients with severealcoholic hepatitis treated with corticosteroids. Gastroenterology. 2016;150:e908.

Zacharias T., Ferreira N., Carin A. J. Preoperative immunonutrition in liverresection-a propensity score matched case-control analysis. Eur J Clin Nutr. 2014;68:964-969.

Badalamenti S., Salerno F., Salmeron J. M. et al. Lack of renal effects of fish oil administration in patients withadvanced cirrhosis and impaired glomerular filtration. Hepatology. 1997;25:313-316.

De Ledinghen V., Beau P., Mannant P. R. et al. Early feeding or enteral nutrition in patients with cirrhosis afterbleeding from esophageal varices? A randomized controlled study. Dig Dis Sci. 1997;42:536-541.

Hebuterne X., Vanbiervliet G. Feeding the patients with upper gastrointestinalbleeding. Curr Opin Clin Nutr Metab Care. 2011;14:197-201.

McClave S. A., Chang W. K. When to feed the patient with gastrointestinalbleeding. Nutr Clin Pract. 2005;20:544-550.




© Сучасна гастроентерологія, 2019
© ТОВ «ВІТ-А-ПОЛ», 2019